These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
873 related articles for article (PubMed ID: 28418232)
41. Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States. Koss CA; Hosek SG; Bacchetti P; Anderson PL; Liu AY; Horng H; Benet LZ; Kuncze K; Louie A; Saberi P; Wilson CM; Gandhi M Clin Infect Dis; 2018 Jan; 66(2):213-219. PubMed ID: 29020194 [TBL] [Abstract][Full Text] [Related]
42. Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial. Velloza J; Donnell D; Hosek S; Anderson PL; Chirenje ZM; Mgodi N; Bekker LG; Marzinke MA; Delany-Moretlwe S; Celum C Lancet HIV; 2022 Oct; 9(10):e680-e689. PubMed ID: 36087612 [TBL] [Abstract][Full Text] [Related]
43. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial. Glidden DV; Das M; Dunn DT; Ebrahimi R; Zhao Y; Stirrup OT; Baeten JM; Anderson PL J Int AIDS Soc; 2021 May; 24(5):e25744. PubMed ID: 34021709 [TBL] [Abstract][Full Text] [Related]
44. Daily and event-driven pre-exposure prophylaxis for men who have sex with men in Belgium: results of a prospective cohort measuring adherence, sexual behaviour and STI incidence. Vuylsteke B; Reyniers T; De Baetselier I; Nöstlinger C; Crucitti T; Buyze J; Kenyon C; Wouters K; Laga M J Int AIDS Soc; 2019 Oct; 22(10):e25407. PubMed ID: 31663257 [TBL] [Abstract][Full Text] [Related]
45. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. Anderson PL; Liu AY; Castillo-Mancilla JR; Gardner EM; Seifert SM; McHugh C; Wagner T; Campbell K; Morrow M; Ibrahim M; Buchbinder S; Bushman LR; Kiser JJ; MaWhinney S Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038282 [TBL] [Abstract][Full Text] [Related]
46. Pre-exposure prophylaxis for men and transgender women who have sex with men in Brazil: opportunities and challenges. Veloso VG; Mesquita F; Grinsztejn B J Int AIDS Soc; 2015; 18(4 Suppl 3):20010. PubMed ID: 26198347 [TBL] [Abstract][Full Text] [Related]
47. Skating on thin ice: stimulant use and sub-optimal adherence to HIV pre-exposure prophylaxis. Hojilla JC; Vlahov D; Glidden DV; Amico KR; Mehrotra M; Hance R; Grant RM; Carrico AW J Int AIDS Soc; 2018 Mar; 21(3):e25103. PubMed ID: 29577616 [TBL] [Abstract][Full Text] [Related]
48. Bacterial sexually transmitted infections among men who have sex with men and transgender women using oral pre-exposure prophylaxis in Latin America (ImPrEP): a secondary analysis of a prospective, open-label, multicentre study. Torres Silva MS; Torres TS; Coutinho C; Ismério Moreira R; da Costa Leite I; Cunha M; da Costa Leite PHA; Cáceres CF; Vega-Ramírez H; Konda KA; Guanira J; Valdez Madruga J; Wagner Cardoso S; Benedetti M; Pimenta MC; Hoagland B; Grinsztejn B; Gonçalves Veloso V; Lancet HIV; 2024 Oct; 11(10):e670-e679. PubMed ID: 39243787 [TBL] [Abstract][Full Text] [Related]
49. The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. Luz PM; Osher B; Grinsztejn B; Maclean RL; Losina E; Stern ME; Struchiner CJ; Parker RA; Freedberg KA; Mesquita F; Walensky RP; Veloso VG; Paltiel AD J Int AIDS Soc; 2018 Mar; 21(3):e25096. PubMed ID: 29603888 [TBL] [Abstract][Full Text] [Related]
50. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial. Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803 [TBL] [Abstract][Full Text] [Related]
51. Same-Day Initiation of Oral Pre-Exposure Prophylaxis is High Among Adolescent Men Who Have Sex With Men and Transgender Women in Brazil. Soares F; Magno L; Pinto JA; Grangeiro A; Bruxvoort K; Greco D; Dourado I J Adolesc Health; 2023 Dec; 73(6S):S26-S32. PubMed ID: 37953005 [TBL] [Abstract][Full Text] [Related]
52. Patterns of daily oral HIV PrEP adherence among people who inject drugs in Ukraine: an analysis of biomarkers. Morozova O; Kornilova M; Makarenko O; Antoniak S; Liulchuk M; Varetska O; Dumchev K J Int AIDS Soc; 2024 Jul; 27 Suppl 3(Suppl 3):e26319. PubMed ID: 39030884 [TBL] [Abstract][Full Text] [Related]
53. PrEP interest and HIV-1 incidence among MSM and transgender women in coastal Kenya. Kimani M; van der Elst EM; Chiro O; Oduor C; Wahome E; Kazungu W; Shally M; Rinke de Wit TF; Graham SM; Operario D; Sanders EJ J Int AIDS Soc; 2019 Jun; 22(6):e25323. PubMed ID: 31194291 [TBL] [Abstract][Full Text] [Related]
54. HPTN 067/ADAPT: Correlates of Sex-Related Pre-exposure Prophylaxis Adherence, Thai Men Who Have Sex With Men, and Transgender Women, 2012-2013. Holtz TH; Chitwarakorn A; Hughes JP; Curlin ME; Varangrat A; Li M; Amico KR; Mock PA; Grant RM; J Acquir Immune Defic Syndr; 2019 Oct; 82(2):e18-e26. PubMed ID: 31490342 [TBL] [Abstract][Full Text] [Related]
55. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE. Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I; BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719 [TBL] [Abstract][Full Text] [Related]
56. Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project. Spinelli MA; Glidden DV; Anderson PL; Gandhi M; McMahan VM; Defechereux P; Schechter M; Veloso VG; Chariyalertsak S; Guanira JV; Bekker LG; Buchbinder SP; Grant RM AIDS Res Hum Retroviruses; 2019 Sep; 35(9):788-793. PubMed ID: 31119944 [TBL] [Abstract][Full Text] [Related]
57. Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. Hiransuthikul A; Janamnuaysook R; Himmad K; Kerr SJ; Thammajaruk N; Pankam T; Phanjaroen K; Mills S; Vannakit R; Phanuphak P; Phanuphak N; J Int AIDS Soc; 2019 Jul; 22(7):e25338. PubMed ID: 31298497 [TBL] [Abstract][Full Text] [Related]
58. Engagement in the pre-exposure prophylaxis (PrEP) cascade among a respondent-driven sample of sexually active men who have sex with men and transgender women during early PrEP implementation in Zimbabwe. Parmley LE; Harris TG; Chingombe I; Mapingure M; Mugurungi O; Rogers JH; Gozhora P; Wu Y; Samba C; Musuka G; Hakim AJ J Int AIDS Soc; 2022 Feb; 25(2):e25873. PubMed ID: 35148029 [TBL] [Abstract][Full Text] [Related]
59. Oral pre-exposure prophylaxis uptake, adherence, and adverse events among South African men who have sex with men and transgender women. Bekker LG; Giovenco D; Baral S; Dominguez K; Valencia R; Sanchez T; McNaghten AD; Zahn R; Yah CS; Sokhela Z; Kaplan R; Phaswana-Mafuya RN; Beyrer C; Sullivan PS South Afr J HIV Med; 2022; 23(1):1405. PubMed ID: 36479416 [TBL] [Abstract][Full Text] [Related]
60. Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study. Grant RM; Pellegrini M; Defechereux PA; Anderson PL; Yu M; Glidden DV; O'Neal J; Yager J; Bhasin S; Sevelius J; Deutsch MB Clin Infect Dis; 2021 Oct; 73(7):e2117-e2123. PubMed ID: 32766890 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]